Independent review of radiology from a multicentre phase II study evaluating intravenous (IV) topotecan (T) with either cisplatin (C) or etoposide (E) in the first line therapy of extensive disease small cell lung cancer (EDSCLC) by validated response rate (RR)

✍ Scribed by S. Gwyther; E. Quoix; P. Cardenal; K. Mattson; M. Lymboura; G. Ross

• Book ID: 117658077
• Publisher: Elsevier Science
• Year: 2001
• Tongue: English
• Weight: 178 KB
• Volume: 37
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/s0959-8049(01)80707-3